Ozempic Competitor Wegovy Could Prevent 1.5M Heart Attacks And Strokes Over 10 Years, Study Reveals
Portfolio Pulse from Benzinga Neuro
A recent study partially financed by Novo Nordisk suggests that the company's weight loss injection, Wegovy, could prevent 1.5 million heart attacks and strokes over 10 years. The study also found that Wegovy could result in 43 million fewer Americans with obesity over the same period. These findings support the initial data from Novo Nordisk's clinical trial, which found that Wegovy reduced the risk of serious heart issues and heart-related death by 20%.
August 17, 2023 | 3:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's weight loss injection, Wegovy, could potentially prevent 1.5 million heart attacks and strokes over 10 years, according to a recent study. This could potentially exert more pressure on insurers to cover obesity medications, which currently cost more than $1,000 per month.
The positive results from the study about Wegovy could increase its demand and acceptance among healthcare providers and patients. This could potentially lead to increased sales and revenue for Novo Nordisk. Additionally, the pressure on insurers to cover obesity medications could also increase the accessibility and affordability of the drug, further boosting its market potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100